| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 14, 2026 | Phase II Trial of Cadonilimab(PD-1/CTLA-4) Combination Regimen Launches in the United States for Perioperative Treatment of Gastric Cancer | HONG KONG, July 14, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that it has entered into a collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to advance a Phase II... |
| May 11, 2026 | Hantavirus cases spark brief surge in pharma and biotech stocks — here’s why trading is so volatile | Several pharmaceutical stocks have surged in wake of a hantavirus outbreak as investors gauge whether they could benefit from developing vaccines.
Moderna, Inovio, and Novavax surged in early trading Monday, but couldn’t sustain some of the... |
| Jun 2, 2024 | WHO members approve steps to bolster health regulations for pandemics | |
| May 25, 2024 | Efforts to draft pandemic treaty falter as countries disagree on steps | |
| Mar 13, 2024 | Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update | – Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 – – CIMERLI® net sales of $52.4 million in the fourth quarter and... |
| May 11, 2022 | Inovio's longtime CEO is out as Covid vaccine laggard throws in the towel on PhIII, pivots to booster | Joseph Kim, the longtime CEO who’s become almost synonymous with Inovio, is leaving the beleaguered company.
Jacqueline Shea
Stepping down to make room for Jacqueline Shea — who first joined Inovio as COO in 2019 — Kim leaves... |
| Jan 25, 2022 | How mRNA And DNA Vaccines Could Soon Treat Cancers, HIV, Autoimmune Disorders And Genetic Diseases | wp_booster error:
td_api_base::get_key : a component with the ID: single_template_2 Key: show_featured_image_on_all_pages is not set.
/home/r8qkakm4wchc/public_html/wp-content/plugins/td-composer/legacy/common/wp_booster/td_api.php (rara-er... |
| Jan 25, 2022 | How mRNA And DNA Vaccines Could Soon Treat Cancers, HIV, Autoimmune Disorders And Genetic Diseases | wp_booster error:
td_api_base::get_key : a component with the ID: single_template_2 Key: show_featured_image_on_all_pages is not set.
/var/web/site/public_html/wp-content/plugins/td-composer/legacy/common/wp_booster/td_api.php (rara-error) ... |
| Nov 30, 2021 | INOVIO Announces Strategy to Address Omicron (B.1.1.529) and Future SARS-CoV-2 Variants | PLYMOUTH MEETING, Pa., Nov. 30, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associ... |
| Nov 10, 2021 | INOVIO Reports Third Quarter 2021 Financial Results | PLYMOUTH MEETING, Pa., Nov. 9, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat people with ca... |
| Nov 9, 2021 | INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S. | FDA Lifts Partial Clinical Hold on INNOVATE Phase 3 Segment
PLYMOUTH MEETING, Pa., Nov. 9, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect peo... |
| Nov 5, 2021 | INOVIO Expands Executive Leadership to Prepare for Commercial Operations | PLYMOUTH MEETING, Pa., Nov. 5, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associate... |
| Nov 3, 2021 | INOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 With Regulatory Authorization from India | PLYMOUTH MEETING, Pa., Nov. 3, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases, and help treat cancer, and HPV-... |
| Oct 21, 2021 | INOVIO Announces Collaboration with Colombia; Memorandum of Understanding Focuses on Protecting Against COVID-19 and Supporting Broader Health Preparedness Initiatives | Memorandum of Understanding builds on recent regulatory authorization from INVIMA to conduct INNOVATE Phase 3 trial for INO-4800, INOVIO's COVID-19 vaccine candidate, in Colombia
Colombia authorization augments recent regulatory authorizati... |
| Oct 12, 2021 | Inovio Pharmaceuticals : Announces Online Preprint Publication of Homologous Boosting Data for its COVID-19 DNA Vaccine Candidate, INO-4800 | PLYMOUTH MEETING, Pa., Oct. 12, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associate... |
| Oct 11, 2021 | Inovio Pharmaceuticals : Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include Colombia following Regulatory Authorization | PLYMOUTH MEETING, Pa., Oct. 11, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associate... |
| Sep 22, 2021 | Inovio Pharmaceuticals : Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico | PLYMOUTH MEETING, Pa., Sept. 22, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associat... |
| Sep 22, 2021 | INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico | News follows recent regulatory authorizations to proceed with the trial in Brazil and the Philippines
INOVIO and partner Advaccine are collaborating on the global Phase 3 trial in regions underserved by COVID-19 vaccines; to focus on Latin ... |
| Aug 26, 2021 | INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800 | INOVIO's global Phase 3 efficacy trial receives authorization to proceed from Brazil; other countries to follow
INOVIO to conduct INNOVATE Phase 3 efficacy trial with partner Advaccine in areas of world in need of COVID-19 vaccines
PLYMOUTH... |
| Aug 26, 2021 | Inovio Pharmaceuticals : Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800 | PLYMOUTH MEETING, Pa., Aug. 26, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associate... |
| Aug 16, 2021 | If You’re Holding Inovio Stock, You Better Have Diamond Hands | August 16, 2021 4 min read This story originally appeared on MarketBeat
Inovio (NYSE: INO) stock is trying to hang on to a small gain after the company reported earnings on August 9. Shares of the biotech company are essentially flat for th... |
| Jun 8, 2021 | INOVIO PHARMACEUTICALS, INC.
Inovio Pharmaceuticals : Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800 | PLYMOUTH MEETING, Pa., June 8, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated... |
| May 17, 2021 | INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors | Dr. Dansey, Seagen's Chief Medical Officer, brings extensive expertise in immuno-oncology and drug development
Appointment of industry leader in drug development expands the Board's diverse industry, clinical development, research and comme... |
| May 17, 2021 | INOVIO PHARMACEUTICALS, INC.
Inovio Pharmaceuticals : Announces Appointment Of Roger Dansey, M.D., to its Board of Directors | PLYMOUTH MEETING, Pa., May 17, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated... |
| May 10, 2021 | Inovio Bulls Could Use a Shot of Good News | May 10, 2021 5 min read This story originally appeared on MarketBeat
Inovio (NASDAQ:INO) stock is staging a mini-rally over the last five days in advance of what is expected to be a mixed earnings report. Analysts are forecasting negative e... |
| May 10, 2021 | INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine | PLYMOUTH MEETING, Pa., May 10, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated... |
| Mar 4, 2021 | INOVIO to Present at Upcoming Investor Conferences in March | PLYMOUTH MEETING, Pa., March 4, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announce... |
| Mar 1, 2021 | INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18 | PLYMOUTH MEETING, Pa., March 1, 2021 /PRNewswire/ -- INOVIO, (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and HPV-associate... |
| Mar 1, 2021 | INOVIO Reports Fourth Quarter 2020 and Year-End Financial Results | PLYMOUTH MEETING, Pa., March 1, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-... |
| Feb 23, 2021 | INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa | PLYMOUTH MEETING, Pa., Feb. 23, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announce... |
| Jan 4, 2021 | Covid-19 roundup: Inovio nabs $3 million and a development partner for its vaccine that's still on partial hold; Slaoui proposes halving Moderna vaccine doses as distribution lags | With its vaccine candidate finally in Phase II, Inovio is bagging $3 million in a partnership deal with Advaccine Biopharmaceuticals Suzhou to develop and commercialize the candidate in Greater China.
Advaccine an... |
| Nov 16, 2020 | Covid-19 roundup: Inovio finally gets PhII rolling — but there's still a clinical hold; Low cost vaccine enters PhI/II in India | Inovio has managed to convince the FDA to sign off on a Phase II trial of its Covid-19 vaccine. But the Phase III portion remains clamped by a partial clinical hold more than a month after it was first imposed.
The little biote... |
| Aug 11, 2020 | Inovio Pharmaceuticals sheds 12% after earnings miss, update on its COVID-19 vaccine | Advertisement
Inovio Pharmaceuticals reported quarterly earnings results Monday that missed Wall Street's expectations.
Shares of the pharmaceutical company shed 12% in premarket trading Tuesday.
The company also said its COVID-19 vaccine c... |
| Jun 30, 2020 | Inovio claims positive results on Covid-19 vaccine but critical data are missing | Inovio Pharmaceuticals on Tuesday said that its investigational Covid-19 vaccine had “positive” results in a small trial. But the company, which has gained more than $4 billion in value since the coronavirus pandemic began, provided none of... |
| Jun 23, 2020 | Covid-19 roundup: $71M from DoD to Inovio; Pigs provide clues on Oxford vaccine; Google lends supercomputing to antiviral hunt | Inovio is locked in a legal standoff with its contract manufacturer preventing it from scaling up their vaccine, but that hasn’t stopped the Department of Defense from backing their technology.
On Tuesday, the DoD gave I... |
| Jun 23, 2020 | Inovio Pharmaceuticals gets $71M from Defense Department for COVID-19 vaccine delivery device | Inovio Pharmaceuticals said Tuesday it has received $71 million from the U.S. Department of Defense to scale up manufacturing of its proprietary device for injecting its COVID-19 vaccine candidate into the skin.
The company began Phase 1 hu... |
| Apr 16, 2020 | Covid-19 vaccine tracker updated to include GSK/Sanofi collaboration | By Jeff Craven
Currently, there are no FDA-approved therapies or vaccines for SARS-CoV-2, the virus that causes Covid-19. The National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes... |
| Apr 9, 2020 | Covid-19 Tracker updates vaccine candidates | By Jeff Craven
On March 11, the World Health Organization classified the Covid-19 outbreak as a pandemic. The disease has reached nearly every country, infecting hundreds of thousands of people and killing thousands.
Curr... |
| Apr 6, 2020 | A second potential COVID-19 vaccine, backed by Bill and Melinda Gates, is entering human testing | A new COVID-19 vaccine candidate is entering Phase 1 clinical human testing today, after the U.S. Food and Drug Administration (FDA) accepted an application from Inovio Pharmaceuticals under the regulator’s Investigational New Drug program.... |
| Apr 6, 2020 | Covid-19 roundup: Inovio gets FDA greenlight to enter human trials; Trump pushes untested malaria drugs again | Inovio, one of the clutch of companies working on a Covid-19 vaccine, has been cleared by the FDA to kick off in-human studies of its experimental vaccine candidate. The Pennsylvania company secured funding from the Coa... |
| Apr 6, 2020 | Vaccine platform technologies to combat emerging infectious diseases | Vaccine platform technologies to combat emerging infectious diseases
06-04-2020
Encouraging progress is being made towards vaccine development against Covid-19. It is essential that we continue to incentivise and fund research into and deve... |
| Apr 1, 2020 | Coronavirus Business Tracker: How The Private Sector Is Fighting The Covid-19 Pandemic | Alain Mérieux, founder of BioMérieux.AFP via Getty Images |
| Mar 30, 2020 | AstraZeneca expands deal with ImaginAb; Ovid posts promising data on Takeda-partnered seizure drug | → On a day when AstraZeneca issued a flurry of updates on three of its blockbuster therapies, the British drugmaker also expanded its deal with ImaginAb, an immuno-oncology imaging company. The partnership gives Astra... |
| Mar 17, 2020 | Inovio Pharmaceuticals Receives $5M Grant to Scale Up Device for COVID-19 Vaccine | Plymouth Meeting, Pa.-based biotechnology company Inovio Pharmaceuticals, Inc. (NASDAQ:INO) received a new $5m grant from the Bill & Melinda Gates Foundation.
The grant will be used to accelerate the testing and scale up of CELLECTRA® 3... |
| Feb 14, 2020 | California lab created a new coronavirus vaccine 3 hours after getting access to the virus’ genetic sequence | Inovio Pharmaceuticals announced it has created a coronavirus vaccine three hours after getting access to the virus’ genetic sequence in mid-January. Based in Pennsylvania, Inovio Pharmaceuticals said its scientists in its laboratory in San... |
| Jan 30, 2020 | FDA outlines product development process to combat Wuhan coronavirus | The FDA on Monday issued a statement explaining how the agency can facilitate the development of investigational products to diagnose, treat and prevent emerging public health threats such as the novel coronavirus (... |
| Sep 18, 2019 | Money Moves: These 5 Philly-area companies just raised millions in VC funding | A handful of Philly-area startups across industries such as biosciences and edtech have announced some late-summer fundraising rounds ranging from just under $1 million up to $50 million.
Late last month, Group K Diagnostics, a Center City-... |
| Oct 24, 2016 | Inovio shares slide after FDA hits it with a hold on lead PhIII HPV program | The FDA has placed Inovio’s lead therapy on clinical hold, halting any new work on the program and putting off a planned start to the Phase III work.
The hold freezes efforts on VGX-3100 as the agency looks for “additional data ... |
| Aug 3, 2016 | As doubts continue to fester, Inovio gets another shove as Roche exits collaboration | Three years after Roche signed up for a $422 million collaboration pact with Inovio $INO on a pair of its early-stage development programs, the pharma giant is bowing out of the last remaining effort in the partnership. ... |
| Dec 17, 2015 | Camel vaccine against MERS could slow camel-to-human infections | Squirting a vaccine up the nostrils of a camel is not the easiest thing in the world to do, Bart Haagmans has discovered. “They are difficult characters,” as he put it. “Sometimes they are a bit grumpy.”
But the effort was worth it for the ... |
| Sep 11, 2013 | What’s attracting big pharma to pre-clinical deals? | Gaining rights to Inovio’s novel vaccines early in development gives Roche more flexibility to shape their development pathways, perform combination trials with its own pipeline, and also puts less upfront cash at risk, Andersen pointed out... |
| Sep 10, 2013 | Inovio inks worldwide licensing deal with Roche to develop early stage DNA vaccines | Electroporation uses an electrical charge to make cell membranes more porous in order to introduce a molecule or DNA code to change the cell’s function, a method called electroporation. It transmits the charge through a scratch on the skin ... |
| Apr 11, 2013 | Vaccine delivery developer secures $3.5M biodefense grant to protect US troops | So far, a team of researchers from Inovio has collaborated with scientists from the U.S. Army Medical Research Institute of Infectious Diseases to advance a DNA vaccine for the Lassa virus, designated as a “Category A” pathogen by the Depar... |
| Jan 16, 2013 | 5 flu vaccines that could shake up the influenza prevention market | Universal vaccines: Biotechnology startup Visterra is developing a monoclonal antibody for universal flu vaccine VIS410 that could not only cover the three most common seasonal strains the widely available flu vaccines protect against, but ... |
| Mar 27, 2012 | Synthetic vaccine developer adds former Merck Vaccines president | The company’s stock jumped 8 percent by the close of trading following the news.
Inovio Pharmaceuticals, based in Blue Bell, Pennsylvania, has three drugs in phase 2 clinical trials to treat cervical cancer, HIV and malaria. Earlier this we... |
| Dec 7, 2011 | Inovio raises $4 million for clinical trials, research | It started out as VGX Pharmaceuticals, which Inovio CEO J. Joseph Kim launched with his Ph.D. professor David Weiner of the Perelman School of Medicine at the University of Pennsylvania, until it did a reverse merger with Inovio in 2009, wh... |
| Oct 14, 2011 | Inovio developing vaccines for HIV, flu and cervical cancer | Q: How did the company get its start?
A: Not unlike many other tech startups. After undergrad at MIT, I worked for Merck and worked to get a hepatitis vaccine launched. I won a doctorate fellowship program and they told me I could do my doc... |
| Synthetic vaccine developer adds former Merck Vaccines president | A synthetic vaccine developer has added a former Merck vaccines president to its board of directors.
Dr. Adel A.F. Mahmoud joined the board of Inovio Pharmaceuticals (NYSE AMEX:INO) this week. He served as president of Merck Vaccines as wel... |
| 5 flu vaccines that could shake up the influenza prevention market | As people in towns and cities across the U.S. feel the clammy grip of the flu epidemic, several biotechnology startups and Big Pharma companies are using innovative technology to develop different approaches to combating influenza and devel... |
| Vaccine delivery developer secures $3.5M biodefense grant to protect US troops | As part of an effort to ensure that the military and public can get rapid access to vaccinations for multiple infections, Inovio Pharmaceuticals (NYSE MKT: INO) has received a $3.5 million grant from National Institute of Allergy and Infect... |
| INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia | PLYMOUTH MEETING, Pa. and GERMANTOWN, Md. and HILDEN, Germany, Feb. 24, 2021 /PRNewswire/ -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with ... |
| Inovio developing vaccines for HIV, flu and cervical cancer | Dr. Joseph Kim is the CEO of Inovio Pharmaceuticals, a Blue Bell, Pennsylvania synthetic vaccine developer that has three drugs in Phase 2 clinical trials for cervical cancer, HIV, and malaria. It started life as VGX Pharmaceuticals which K... |
| Inovio raises $4 million for clinical trials, research | Inovio Pharmaceuticals (NYSE:INO) has closed a public offering in which it raised $4 million. It said in a statement that it will use the proceeds toward clinical trial and research and development expenses.
Inovio Pharmaceuticals, a Blue B... |
| What’s attracting big pharma to pre-clinical deals? | Roche’s move to skip over Inovio’s (NYSE: INO) late stage drugs for cervical cancer and Hepatitis C and make a beeline for its preclinical DNA vaccines for prostate cancer and Hep B was initially a little puzzling. Investors have preferred ... |
| Inovio inks worldwide licensing deal with Roche to develop early stage DNA vaccines | In a move that gives Inovio Pharmaceuticals (NYSE: INO) its second big pharma partnership, it’s signed a global licensing deal with Swiss drug developer Roche (OTCQX: RHHBY) for its DNA vaccines for Hepatitis B and prostate cancer. The deal... |
| INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel | PLYMOUTH MEETING, Pa., March 15, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announc... |
